TET2 Dysfunction Drives Epigenetic Changes in Myelodysplastic Syndromes

A new study led by researchers from the Chinese Academy of Medical Sciences has produced the first base-resolution DNA methylome of human hematopoietic stem cells (HSCs) from patients with myelodysplastic syndromes (MDS), offering a detailed picture of how DNA methylation is disrupted in this disease. The research reveals that loss of TET2 function, a known regulator of DNA demethylation, contributes directly to the abnormal methylation and gene expression changes that underlie MDS development.

Through single-base resolution sequencing, the investigators compared DNA methylation patterns in HSCs from individuals with high-risk MDS to those from healthy donors. Their analysis uncovered extensive methylation dysregulation, with CpG island regions showing widespread hypermethylation and repetitive elements such as Alu sequences exhibiting hypomethylation. These methylation changes occurred in gene regions linked to cancer-associated processes, external signaling pathways, and transcriptional regulatory networks essential for HSC maintenance.

Key hematopoietic regulators emerged as central targets of these DNA modifications. The transcriptional control region of GFI1 was found to be hypermethylated, leading to decreased gene expression, while BMI1 displayed hypomethylation associated with increased expression. These findings highlight how shifts in DNA methylation may alter the balance of gene networks that control normal HSC differentiation and self-renewal.

To clarify the role of TET2 in these processes, the researchers used mouse models of MDS along with Tet2-knockout mice. They demonstrated that TET2 directly mediates demethylation at the Gfi1 promoter, and that Tet2 loss triggers promoter hypermethylation, transcriptional silencing of Gfi1, and aberrant expansion of the HSC and progenitor cell pool. In aged Tet2-deficient mice, these changes evolved into MDS-like features, suggesting that the TET2-GFI1 axis helps restrain malignant transformation through its influence on stem cell aging.

By integrating analysis of primary patient samples with genetically engineered mouse models, the research, published in Immunity & Inflammation, connects epigenetic enzyme mutations, DNA methylation abnormalities, and dysregulated transcription factor expression into a coherent pathogenic cascade. The identification of the TET2-GFI1 axis as an "epigenetic brake" that suppresses MDS offers a new conceptual framework for understanding disease initiation at the HSC level.